Do We Really Need to Keep Redesigning β2-agonists for the Management of Asthma?
Current Drug Delivery,
David Van Ly and Brian G.G. OliverAffiliation:
School of Medical & Molecular Biosciences, University of Technology Sydney, Building 4, Level 6, City Campus, P.O Box: 123 Broadway NSW 2007 Australia.
AbstractThere is an enormous drive to refine therapeutic designs and delivery systems, but in this review we ask if this is always the right direction? We choose to play devil's advocate, and argue that refining drug design is not always needed, and what is actually needed is a greater understanding of the biology of the disease. Here we focus on asthma and the β2-agonist group of bronchodilators as an example of how a class of therapeutic has been developed and continues to be developmentally refined. In this review, we define viralinduced exacerbations as the greatest cause of lung attacks and the most crucial time β2-agonist therapy is needed. We explore the reasons why β2-agonist therapy fails in patients with rhinovirus-induced exacerbations, and explain why further “engineered” β2-agonist therapies are likely to continue to fail in this subset of asthmatic population. We justify our perspective by returning to the biology that underlies the cause of disease and highlight the need for “more research” into alternative therapies for this population of asthmatic patients.
β2-agonists, desensitization, exacerbations, leukotrienes, prostaglandins, rhinovirus.
Download Free Order Reprints Order Eprints Rights and Permissions